GTC Biotherapeutics (fka GTCB)

[vinmantoo]

jessellivermore,

I agree that this paper is very significant. It provides a molecular mechanism for why ATIII could improve survial in sepsis patients. It also explains why heparin might block the effects of ATIII. Heparin could compete with heparin like cell surface receptors for ATIII binding, and thus, inhibit ATIII binding to monocytes. This makes me more confident in the DIC trials of rATIII.

Nice find Dew,

Vinny